These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32644127)

  • 1. Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.
    Kublin JG; Murphy SC; Maenza J; Seilie AM; Jain JP; Berger D; Spera D; Zhao R; Soon RL; Czartoski JL; Potochnic MA; Duke E; Chang M; Vaughan A; Kappe SHI; Leong FJ; Pertel P; Prince WT;
    Clin Infect Dis; 2021 Oct; 73(7):e2407-e2414. PubMed ID: 32644127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
    Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
    Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.
    White NJ; Duong TT; Uthaisin C; Nosten F; Phyo AP; Hanboonkunupakarn B; Pukrittayakamee S; Jittamala P; Chuthasmit K; Cheung MS; Feng Y; Li R; Magnusson B; Sultan M; Wieser D; Xun X; Zhao R; Diagana TT; Pertel P; Leong FJ
    N Engl J Med; 2016 Sep; 375(12):1152-60. PubMed ID: 27653565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.
    Kuhen KL; Chatterjee AK; Rottmann M; Gagaring K; Borboa R; Buenviaje J; Chen Z; Francek C; Wu T; Nagle A; Barnes SW; Plouffe D; Lee MC; Fidock DA; Graumans W; van de Vegte-Bolmer M; van Gemert GJ; Wirjanata G; Sebayang B; Marfurt J; Russell B; Suwanarusk R; Price RN; Nosten F; Tungtaeng A; Gettayacamin M; Sattabongkot J; Taylor J; Walker JR; Tully D; Patra KP; Flannery EL; Vinetz JM; Renia L; Sauerwein RW; Winzeler EA; Glynne RJ; Diagana TT
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5060-7. PubMed ID: 24913172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
    Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
    McKeage K; Scott L
    Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized feasibility trial comparing four antimalarial drug regimens to induce
    Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T
    Elife; 2018 Feb; 7():. PubMed ID: 29482720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
    Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ
    Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
    Lyke KE; Berry AA; Mason K; Idris AH; O'Callahan M; Happe M; Strom L; Berkowitz NM; Guech M; Hu Z; Castro M; Basappa M; Wang L; Low K; Holman LA; Mendoza F; Gordon IJ; Plummer SH; Trofymenko O; Strauss KS; Joshi S; Shrestha B; Adams M; Chagas AC; Murphy JR; Stein J; Hickman S; McDougal A; Lin B; Narpala SR; Vazquez S; Serebryannyy L; McDermott A; Gaudinski MR; Capparelli EV; Coates EE; Wu RL; Ledgerwood JE; Dropulic LK; Seder RA;
    Lancet Infect Dis; 2023 May; 23(5):578-588. PubMed ID: 36708738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report.
    van Meer MP; Bastiaens GJ; Boulaksil M; de Mast Q; Gunasekera A; Hoffman SL; Pop G; van der Ven AJ; Sauerwein RW
    Malar J; 2014 Jan; 13():38. PubMed ID: 24479524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.
    Murphy SC; Duke ER; Shipman KJ; Jensen RL; Fong Y; Ferguson S; Janes HE; Gillespie K; Seilie AM; Hanron AE; Rinn L; Fishbaugher M; VonGoedert T; Fritzen E; Kappe SH; Chang M; Sousa JC; Marcsisin SR; Chalon S; Duparc S; Kerr N; Möhrle JJ; Andenmatten N; Rueckle T; Kublin JG
    J Infect Dis; 2018 Feb; 217(5):693-702. PubMed ID: 29216395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
    Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
    J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
    Watts RE; Odedra A; Marquart L; Webb L; Abd-Rahman AN; Cascales L; Chalon S; Rebelo M; Pava Z; Collins KA; Pasay C; Chen N; Peatey CL; Möhrle JJ; McCarthy JS
    PLoS Med; 2020 Aug; 17(8):e1003203. PubMed ID: 32822347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in total and differential leukocyte counts during the clinically silent liver phase in a controlled human malaria infection in malaria-naïve Dutch volunteers.
    van Wolfswinkel ME; Langenberg MCC; Wammes LJ; Sauerwein RW; Koelewijn R; Hermsen CC; van Hellemond JJ; van Genderen PJ
    Malar J; 2017 Nov; 16(1):457. PubMed ID: 29126422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.
    Blanshard A; Hine P
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD004529. PubMed ID: 33459345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat controlled human malaria infection of healthy UK adults with blood-stage
    Salkeld J; Themistocleous Y; Barrett JR; Mitton CH; Rawlinson TA; Payne RO; Hou MM; Khozoee B; Edwards NJ; Nielsen CM; Sandoval DM; Bach FA; Nahrendorf W; Ramon RL; Baker M; Ramos-Lopez F; Folegatti PM; Quinkert D; Ellis KJ; Poulton ID; Lawrie AM; Cho JS; Nugent FL; Spence PJ; Silk SE; Draper SJ; Minassian AM
    Front Immunol; 2022; 13():984323. PubMed ID: 36072606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.
    Ling J; Baird JK; Fryauff DJ; Sismadi P; Bangs MJ; Lacy M; Barcus MJ; Gramzinski R; Maguire JD; Kumusumangsih M; Miller GB; Jones TR; Chulay JD; Hoffman SL;
    Clin Infect Dis; 2002 Oct; 35(7):825-33. PubMed ID: 12228819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity.
    Hickey BW; Lumsden JM; Reyes S; Sedegah M; Hollingdale MR; Freilich DA; Luke TC; Charoenvit Y; Goh LM; Berzins MP; Bebris L; Sacci JB; De La Vega P; Wang R; Ganeshan H; Abot EN; Carucci DJ; Doolan DL; Brice GT; Kumar A; Aguiar J; Nutman TB; Leitman SF; Hoffman SL; Epstein JE; Richie TL
    Malar J; 2016 Jul; 15(1):377. PubMed ID: 27448805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.